SUBPART D—Provisional Health Effects Guidelines (§795.225 to §795.250)
- 795.225—Dermal pharmacokinetics of DGBE and DGBA.
- 795.228—Oral/dermal pharmacokinetics.
- 795.231—Pharmacokinetics of isopropanal.
- 795.232—Inhalation and dermal pharmacokinetics of commercial hexane.
- 795.250—Developmental neurotoxicity screen.